Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse, der evaluerer pantoprazol hos børn med gastroøsofageal reflukssygdom (GERD)

1. september 2026 opdateret af: Wyeth is now a wholly owned subsidiary of Pfizer

En multicenter, randomiseret, dobbeltblind undersøgelse af de kliniske resultater, sikkerhed og tolerabilitet af flere doser af pantoprazolnatrium enterisk coated sfæroider hos børn i alderen 1 til 5 med endoskopisk bevist symptomatisk gastroøsofageal reflukssygdom (GERD)

To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.

Studieoversigt

Status

Afsluttet

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

60

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Alberta
      • Edmonton, Alberta, Canada, T6G 2B7
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Canada, A1B 3V6
    • Ontario
      • Hamilton, Ontario, Canada, L8N 3Z5
      • London, Ontario, Canada, N6A 4G5
      • Ottawa, Ontario, Canada, K1H 8L1
    • Quebec
      • Montreal, Quebec, Canada, H3H 1P3
      • Montreal, Quebec, Canada, H3T 1C5
    • Alabama
      • Mobile, Alabama, Forenede Stater, 36604
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85016
    • California
      • Oakland, California, Forenede Stater, 94609
      • Orange, California, Forenede Stater, 92868
      • Sacramento, California, Forenede Stater, 95819
      • San Diego, California, Forenede Stater, 92103
    • Delaware
      • Wilmington, Delaware, Forenede Stater, 19803
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20010
    • Florida
      • Gainesville, Florida, Forenede Stater, 32610
      • Jacksonville, Florida, Forenede Stater, 32207
      • Miami, Florida, Forenede Stater, 33101
      • Orlando, Florida, Forenede Stater, 32806
      • Pensacola, Florida, Forenede Stater, 32504
    • Illinois
      • Peoria, Illinois, Forenede Stater, 61603
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40536
      • Louisville, Kentucky, Forenede Stater, 40202
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
      • Boston, Massachusetts, Forenede Stater, 02115
    • Michigan
      • Flint, Michigan, Forenede Stater, 48503
      • Southfield, Michigan, Forenede Stater, 48075
    • Mississippi
      • Jackson, Mississippi, Forenede Stater, 39216
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68105
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89102
    • New Jersey
      • Egg Harbor, New Jersey, Forenede Stater, 08234
      • Morristown, New Jersey, Forenede Stater, 07962
    • New York
      • Buffalo, New York, Forenede Stater, 14222
      • New York, New York, Forenede Stater, 10032
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
    • Pennsylvania
      • Danville, Pennsylvania, Forenede Stater, 17822-1320
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
    • Texas
      • Houston, Texas, Forenede Stater, 77030
      • Temple, Texas, Forenede Stater, 76508
    • Virginia
      • Norfolk, Virginia, Forenede Stater, 23507
    • West Virginia
      • Charleston, West Virginia, Forenede Stater, 25304
      • Huntington, West Virginia, Forenede Stater, 25701-3655
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53215

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

1 år til 5 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Ability to undergo endoscopy with required biopsy
  • Ages 1 through 5 years
  • Endoscopically confirmed GERD by positive endoscopic evidence of reflux related esophagitis or positive histologic evidence of esophagitis consistent with GERD Other inclusions apply.

Exclusion Criteria:

  • History or presence of upper gastrointestinal anatomic or motor disorders
  • Known current or active cow's milk allergy
  • Malignancy
  • Other exclusions apply.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: 1

Low Dose Pantoprazole (Approximately 0.3 mg/kg)

Pediatric spheroids administered once daily for 8 weeks.

Aktiv komparator: 2

Medium Dose Pantoprazole (Approximately 0.6 mg/kg)

Pediatric spheroids administered once daily for 8 weeks.

Aktiv komparator: 3

High Dose Pantoprazole (Approximately 1.2 mg/kg)

Pediatric spheroids administered once daily for 8 weeks.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Weekly Gastroesophageal Reflux Disease (GERD) Symptom Scores (WGSS)
Tidsramme: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, and Final Week

Weekly GERD symptom score (WGSS) is the sum of 5 selected individual weekly GERD mean frequency scores: vomiting/regurgitation, choking/gagging, refusal to eat, difficulty swallowing and abdominal/belly pain. Symptoms were assessed using a parent-administered questionnaire. The score for each individual symptom ranged from 0 (no symptoms) to 3 (highest frequency of symptoms), giving a WGSS range of 0-15. Change = score at week of assessment minus baseline score. Final Week was defined as the last 7 days of symptom scores collected during the treatment period.

Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, and Final Week

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Individual Weekly Mean Frequency Score for Each Gastroesophageal Reflux Disease (GERD) Symptom Score From Baseline to Final Week
Tidsramme: Baseline and 8 weeks

Selected symptoms of GERD were assessed using a parent-administered questionnaire. The score for each symptom ranged from 0 (no symptom) to 3 (highest frequency of symptom), The weekly mean score was the sum of daily scores that week, divided by the number of days with scores for that week. Change = final week score minus baseline score. Final week was defined as the last 7 days of scores collected in the treatment period.

Baseline and 8 weeks
Change in Individual Weekly Mean Score For Each Respiratory Symptom From Baseline
Tidsramme: Baseline and 8 weeks

Individual respiratory symptoms weekly score was calculated as the average score / number of events for a patient in the corresponding week if the patient answered a question ≥3 times that week. Change = final week score minus baseline score. Final week was defined as the last 7 days of scores collected in the treatment period.

Baseline and 8 weeks
Number of Patients With "Healed" Erosive Esophagitis (EE) at End of Study
Tidsramme: 8 weeks

Healed EE was defined as a modified Hetzel-Dent (HD) score <2 on endoscopy at end of study. HD is a standardized rating scale for grading esophageal damage and severity of gastroesophageal reflux disease (GERD). HD score ranges from 0 (normal mucosa) to 4 (deep peptic ulceration).

8 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Studieleder: Medical Monitor, Wyeth is now a wholly owned subsidiary of Pfizer

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. maj 2006

Primær færdiggørelse (Faktiske)

1. april 2008

Studieafslutning (Faktiske)

1. april 2008

Datoer for studieregistrering

Først indsendt

7. marts 2006

Først indsendt, der opfyldte QC-kriterier

7. marts 2006

Først opslået (Anslået)

9. marts 2006

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner